Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 17;15(3):566.
doi: 10.3390/cancers15030566.

Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer

Jorge Esteban-Villarrubia  1 , Javier Torres-Jiménez  2 , Carolina Bueno-Bravo  3 , Rebeca García-Mondaray  4 , José Daniel Subiela  5 , Pablo Gajate  6
Affiliations
Review

Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer

Jorge Esteban-Villarrubia et al. Cancers (Basel). .

Abstract

Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the current standard of care for muscle-invasive bladder cancer (MIBC). However, less than half of patients are candidates for this treatment, and 50% will develop metastatic disease. Adjuvant chemotherapy could be offered if neoadjuvant treatment has not been administered for suitable patients. It is important to reduce the risk of systemic recurrence and improve the prognosis of localized MIBC. Systemic therapy for metastatic urothelial carcinoma has evolved in recent years. Immune checkpoint inhibitors and targeted agents, such as antibody-drug conjugates or FGFR inhibitors, are new therapeutic alternatives and have shown their benefit in advanced disease. Currently, several clinical trials are investigating the role of these drugs, as monotherapy and in combination with chemotherapy, in the neoadjuvant and adjuvant settings with promising outcomes. In addition, the development of predictive biomarkers could predict responses to neoadjuvant therapies.

Keywords: adjuvant; chemotherapy; immunotherapy; muscle-invasive bladder cancer; neoadjuvant; targeted agents.

PubMed Disclaimer

Conflict of interest statement

PG received travel and educational support from Pfizer, Merck Serono, Ipsen, Sanofi-Genzyne, Roche and Jansen and has served as advisor and delivered lectures for BMS, MSD, Merck Serono, Pfizer, Ipsen, Roche, Adacap, Eisai, Sanofi-Genzyme, Novartis, Astellas and Jansen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Patel V.G., Oh W.K., Galsky M.D. Treatment of Muscle-invasive and Advanced Bladder Cancer in 2020. CA A Cancer J. Clin. 2020;70:404–423. doi: 10.3322/caac.21631. - DOI - PubMed
    1. Powles T., Bellmunt J., Comperat E., De Santis M., Huddart R., Loriot Y., Necchi A., Valderrama B.P., Ravaud A., Shariat S.F., et al. Bladder Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. Ann. Oncol. 2022;33:244–258. doi: 10.1016/j.annonc.2021.11.012. - DOI - PubMed
    1. Cowan N.G., Chen Y., Downs T.M., Bochner B.H., Apolo A.B., Porter M.P., La Rochelle J.C., Amling C.L., Koppie T.M. Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions. Adv. Urol. 2014;2014:746298. doi: 10.1155/2014/746298. - DOI - PMC - PubMed
    1. Stein J.P., Lieskovsky G., Cote R., Groshen S., Feng A.-C., Boyd S., Skinner E., Bochner B., Thangathurai D., Mikhail M., et al. Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1054 Patients. JCO. 2001;19:666–675. doi: 10.1200/JCO.2001.19.3.666. - DOI - PubMed

LinkOut - more resources